成人类型IDH突变结质瘤的质子疗法:Proglio-1,一个多中心的回顾性研究
Nicolas Goliot1,2, Emmanuel Jouglar3,4,5, Julian Jacob6
1Radiation Oncology Department, François Baclesse Comprehensive Cancer Center, Caen, 14000, France. nicolas.goliot@gmail.com.
Radiation oncology (London, England)
|August 5, 2025
概括
质子疗法对异酸脱酶 (IDH) 突变质瘤显示出有利的中期结果,表现出良好的耐受性和有效性. 这种先进的放射治疗技术为成年人中的这些脑瘤提供了有前途的治疗选择.
科学领域:
- 神经瘤学神经瘤学
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- IDH突变质瘤主要影响年轻成年人,需要维持生活质量的治疗.
- 标准的光子辐射疗法可能会对认知和长期福祉产生负面影响.
- 与光子辐射疗法相比,质子疗法可以更好地节省健康组织.
研究的目的:
- 评估成年IDH突变性质瘤中质子疗法的中期生存和毒性.
- 在多中心队列中评估无进展生存率 (PFS) 和总生存率 (OS).
- 分析复发和辐射诱导对比增强 (RICE) 的模式.
主要方法:
- 对90名IDH突变质瘤患者进行了回顾性分析,这些患者接受了质子疗法治疗.
- 卡普兰-梅尔对OS和PFS的分析,用日志级和Cox模型进行比较.
- 毒性,RICE和复发模式的评估.
主要成果:
- 随访时间中位数为27.3个月;中位数PFS为42.5个月,中位数OS未达到.
- 世界卫生组织 (WHO) 的较高等级 (3-4) 显示PFS明显低于WHO 2级.
- 质子疗法被很好地容忍,严重毒性最小,可控RICE.
结论:
- 质子疗法对IDH突变质瘤具有有利的中期耐受性和疗效概况.
- 这种模式是治疗这些瘤的可行选择,特别是在年轻患者中.
- 进一步的研究应侧重于长期结果和比较有效性.
相关概念视频
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K